Mesoblast (MESO) is trading up at $14.22 (+0.99%), as of the latest quote. It operates in the Health Care sector.
| FY2016Jun 2016 | FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $42.5M | $2.41M | $17.3M | $16.7M | $32.2M | $7.43M | $10.2M | $7.50M | $5.90M | $17.2M |
| Growth (year over year) | — | −94.3% | +618.9% | −3.6% | +92.3% | −76.9% | +37.4% | −26.5% | −21.3% | +191.4% |
| Gross profit | — | — | — | — | — | — | — | $7.50M | $5.90M | $12.1M |
| Gross margin | — | — | — | — | — | — | — | 100.0% | 100.0% | 70.2% |
| Net income | −$4.13M | −$76.8M | −$35.3M | −$89.8M | −$77.9M | −$98.8M | −$91.3M | −$81.9M | −$88.0M | −$102.1M |
| Net margin | −9.7% | −3184.7% | −203.5% | −537.0% | −242.4% | −1329.2% | −894.6% | −1091.7% | −1490.3% | −593.9% |
| EPS (diluted) | −$0.01 | −$0.19 | −$0.08 | −$0.00 | −$0.15 | −$0.16 | −$0.13 | −$0.11 | −$0.09 | −$0.08 |
| Balance sheet | ||||||||||
| Cash and equivalents | $80.9M | $45.8M | $37.8M | $50.4M | $129.3M | $136.9M | $60.4M | $71.3M | $63.0M | $161.6M |
| Total assets | — | $655.7M | $692.4M | $652.1M | $733.6M | $744.7M | $662.1M | $669.4M | $669.2M | $784.7M |
| Total liabilities | — | $138.9M | $146.4M | $171.1M | $184.3M | $163.3M | $165.1M | $167.6M | $188.8M | $187.2M |
| Shareholders' equity | $528.2M | $516.8M | $546.0M | $481.1M | $549.3M | $581.4M | $497.0M | $501.8M | $480.4M | $597.4M |
| Cash flow | ||||||||||
| Operating cash flow | −$88.0M | −$95.5M | −$75.0M | −$57.8M | −$50.4M | −$100.7M | −$65.8M | −$63.3M | −$48.5M | −$50.0M |
| Capital expenditure | — | — | — | — | — | — | — | $264.0K | $271.0K | $680.0K |
| Free cash flow | — | — | — | — | — | — | — | −$63.5M | −$48.7M | −$50.6M |
| Q1 FY22Sep 2021 | Q2 FY22Dec 2021 | Q3 FY22Mar 2022 | Q4 FY22†Jun 2022 | Q1 FY23Sep 2022 | Q2 FY23Dec 2022 | Q3 FY23Mar 2023 | Q4 FY23†Jun 2023 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.59M | $2.38M | $2.01M | $2.22M | $1.50M | $2.13M | $1.94M | $1.93M |
| Growth (year over year) | +175.4% | +6.3% | +5.0% | +12.7% | −58.2% | −10.4% | −3.6% | −13.4% |
| Net income | −$22.6M | −$25.9M | −$21.3M | −$21.5M | −$16.9M | −$24.5M | −$18.6M | −$21.9M |
| Net margin | −630.1% | −1088.8% | −1059.3% | −965.1% | −1123.4% | −1147.4% | −959.3% | −1138.6% |
| EPS (diluted) | −$0.03 | −$0.04 | −$0.03 | −$0.03 | −$0.02 | −$0.03 | −$0.03 | −$0.02 |
| Balance sheet | ||||||||
| Cash and equivalents | $116.0M | $94.8M | $76.8M | $60.4M | $85.5M | $67.6M | $48.8M | $71.3M |
| Total assets | $721.8M | $704.4M | $681.7M | $662.1M | $684.5M | $668.1M | $650.4M | $669.4M |
| Total liabilities | $162.1M | $168.9M | $164.6M | $165.1M | $161.7M | $168.1M | $168.3M | $167.6M |
| Shareholders' equity | $559.7M | $535.5M | $517.1M | $497.0M | $522.8M | $500.0M | $482.2M | $501.8M |
| Cash flow | ||||||||
| Operating cash flow | −$18.2M | −$18.2M | −$15.5M | −$13.9M | −$14.3M | −$16.5M | −$16.3M | −$16.3M |
| Capital expenditure | — | — | $49.0K | — | — | — | $0 | $214.0K |
| Free cash flow | — | — | −$15.5M | — | — | — | −$16.3M | −$16.5M |
From Mesoblast's 20-F and 6-K filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
No recent news mentioning Mesoblast in our feed yet.